Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this article, the authors reported that calcipotriol/betamethasone dipropionate aerosol foam significantly improved scalp psoriasis symptoms in three patients by reducing itching and improving flaky patches within a four-week treatment period, confirming its efficacy and enhanced skin penetration compared to older formulations.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.

This review discusses the use of topical immunotherapy for severe alopecia areata and resistant viral warts, highlighting diphencyprone's advantages and the need for careful handling to avoid staff sensitisation; it reports no new clinical results.

This study demonstrated the high effectiveness and safety of tofacitinib, a pan-JAK inhibitor, in treating severe forms of alopecia areata, although it is not yet FDA-approved for this condition.

In this study, tofacitinib and baricitinib showed comparable efficacy and tolerability under unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe alopecia areata over 24 weeks; however, the unorthodox baricitinib regimen yielded a lower effectiveness in severe cases, emphasizing the importance of adherence to guideline-recommended dosing.

This source reports that tofacitinib and ruxolitinib showed potential efficacy and acceptable safety profiles in treating various autoimmune disorders, including alopecia areata and psoriasis, based on a review of clinical studies, while recommending physicians consider the individual risks and benefits.

This study found that leflunomide combined with prednisone showed good efficacy and tolerance in treating lupus nephritis where cyclophosphamide was ineffective or intolerable.

This paper reviews the use of tacrolimus for various conditions, noting its effectiveness in treating certain skin disorders but highlighting that some findings remain anecdotal due to limited case numbers.

This study found that both tofacitinib and methotrexate effectively reduced hair loss and psychological distress in patients with moderate-to-severe alopecia areata, but tofacitinib showed much greater efficacy. Both treatments had similar safety profiles, with no serious adverse effects reported.

This source describes a previous case report that combined anthralin and calcipotriene to treat alopecia areata, showing promising results, but highlights that further research is needed to understand the mechanisms and potential benefits of this combination therapy.

In this study, topical MR blockade improved delayed wound healing in glucocorticoid-pretreated mice by promoting anti-inflammatory macrophages and enhancing angiogenesis.

The researchers reported that a newly developed photo-cross-linked hydrogel with multifunctional properties, including antimicrobial and antioxidant effects, significantly improved diabetic wound healing, achieving over 90% wound closure in seven days in vivo.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This study found that among patients with twenty-nail dystrophy, those treated with oral cyclosporine in combination with a dietary supplement showed significantly better improvement in nail condition and quality of life than those treated with the supplement alone.

This case report suggests that JAK inhibitors like tofacitinib may effectively treat alopecia in patients with complex cases involving both rheumatological and dermatological conditions.

This study evaluated the efficacy and safety of tofacitinib for treating severe alopecia areata in five patients, finding that three responded favorably with mild side effects, supporting its potential use based on existing research.

In this study, quercetin and kaempferol, two plant-derived flavonoids, showed stronger binding affinities to JAK3 kinase and moderate binding to 5-alpha reductase type 2, suggesting their potential as natural treatments for androgenetic alopecia, with quercetin demonstrating suitable properties for topical application.

This study suggests that Janus kinase inhibitors may offer a potential treatment option for refractory lichen planopilaris and frontal fibrosing alopecia, showing positive response rates between 42% and 100%, though evidence quality is low.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

In this case report, two female patients with refractory systemic lupus erythematosus showed significant improvement after treatment with the JAK inhibitor upadacitinib, indicating potential as a promising option for difficult cases, although further research is needed to confirm its broader safety and efficacy.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

This study investigated the efficacy and safety of a gel combining topical calcipotriol and steroid for alopecia areata. It found the combination worked similarly to steroids alone in reducing hair loss, but with fewer side effects.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.

This study found that tofacitinib was an effective and well-tolerated treatment for alopecia areata, with significant to moderate hair regrowth in 78% of patients observed.

Dovobet ointment used overnight effectively reduces scalp psoriasis severity and itch.

In this case series, dual-targeted therapy was observed to provide promising clinical responses in refractory inflammatory bowel disease, with 88.23% to 100% response rates across 9 months and an endoscopic response in 88.89% of evaluated patients, though some adverse events occurred.

This study found that BD 1/4 dilution was the most effective corticosteroid concentration for intralesional injection to treat localized alopecia areata in adults, with fewer adverse effects than TA.

This study compared oral tofacitinib and methotrexate in treating moderate-to-severe alopecia areata, finding that tofacitinib was more effective at reducing SALT scores and improving scalp hair assessment PRO scores, though both treatments reduced psychological distress similarly without serious adverse effects.

This study found that higher concentrations of topical diphenylcyclopropenone, especially when prepared with acetone, showed better stability over 6 months compared to lower concentrations.